Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
Oxytocin (Pitocin)
Also known as: Pitocin, Syntocinon, Oxt, The Love Hormone, The Bonding Hormone
Confidence
Updated 2026-03-18
Oxytocin is a nine-amino acid endogenous neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary. FDA-approved (Pitocin) for labor induction and postpartum hemorrhage, it is also widely investigated for social bonding, anxiety, autism spectrum disorder, PTSD, and relationship enhancement. It plays a central role in maternal bonding, social cognition, and stress regulation.
Class
Neuropeptide Hormone
Routes
Intravenous, Intramuscular, Intranasal, Sublingual
Half-Life
IV: ~3–5 minutes | Intranasal: functional CNS effects persist 1–4 hours
Oxytocin binds to the oxytocin receptor (OXTR), a G-protein coupled receptor expressed in the brain (amygdala, hypothalamus, nucleus accumbens), uterus, breast, and cardiovascular system. In the brain, it modulates social cognition, reduces amygdala reactivity (anxiety reduction), enhances trust and empathy, and promotes pair bonding. Peripherally, it stimulates uterine contractions (labor) and myoepithelial contraction (milk let-down). It also modulates the HPA stress axis.
Half-Life
IV: ~3–5 minutes | Intranasal: functional CNS effects persist 1–4 hours
Bioavailability
IV: 100% (peripheral). Intranasal: variable, estimated 2–8% reaches brain (bypasses BBB via olfactory and trigeminal pathways).
FDA-approved: Induction/augmentation of labor, control of postpartum bleeding, incomplete abortion. Off-label/research: social anxiety, ASD social deficits, PTSD, depression, couples therapy adjunct, sexual dysfunction, chronic pain.
Well-established for obstetric indications (decades of clinical use). For behavioral/psychiatric uses: over 200 clinical trials of intranasal oxytocin have been published with mixed results. Initial promising findings for ASD social cognition (Hollander et al.) were not consistently replicated in larger trials (SOAR trial in children with ASD showed no benefit). Meta-analyses suggest small effects on social cognition and anxiety in specific contexts. The "love hormone" narrative is oversimplified — effects are context-dependent and modulated by individual differences.
Human Studies
250
Animal Studies
500
IV (obstetric): water intoxication (antidiuretic effect at high doses), uterine hyperstimulation, fetal distress. Black box warning for elective labor induction. Intranasal (behavioral): generally well-tolerated. Nasal irritation, headache. Paradoxical effects in some individuals (increased anxiety in social threat contexts). Long-term effects of repeated intranasal use unknown. May affect social decision-making in unexpected ways (increased in-group favoritism).
FDA-approved for obstetric indications. Intranasal formulations available through compounding pharmacies. Off-label psychiatric use growing despite mixed evidence. Not scheduled or controlled.
Drug Interactions: Prostaglandins (potentiate uterine effects). May interact with vasopressin analogs. Theoretical interactions with SSRIs, anxiolytics. Monitoring: Fetal heart rate and uterine tone (obstetric). Behavioral/symptom assessment (psychiatric use). Research Gaps: Why do intranasal oxytocin trials yield inconsistent results? Individual differences in OXTR genetics. Optimal dosing for behavioral effects. Long-term safety of chronic intranasal use.
IV (Pitocin — obstetric, FDA-approved)
Common Range
0.5–2 mU/min initial, titrated to 1–40 mU/min
Timing
During labor, under continuous fetal monitoring
Frequency
Continuous IV infusion
Cycling
Duration of labor
Important Note
FDA-approved for obstetric use. Must be administered in supervised hospital/birth center setting with continuous fetal monitoring.
Intranasal (behavioral/psychiatric — off-label)
Common Range
20–40 IU per dose
Timing
30–45 minutes before social interaction or therapy session
Frequency
Once to twice daily (research protocols vary widely)
Cycling
Variable — acute single dose (research) or daily for 4–12 weeks (treatment trials)
Important Note
Off-label for behavioral/psychiatric indications. Compounded intranasal spray. Effects are context-dependent. Evidence base is mixed.
Connect with a verified provider offering Oxytocin therapy near you.
Melanocortin Receptor Agonist (Sexual Health)
Bremelanotide is a synthetic melanocortin receptor agonist FDA-approved (Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the commercially developed form of the research peptide PT-141. Unlike PDE5 inhibitors, it acts centrally through melanocortin pathways in the brain to enhance sexual desire rather than peripheral vascular mechanisms.
Sexual Health
PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is unique among sexual health therapeutics in that it acts centrally through the nervous system rather than peripherally on blood flow.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.